VR Logo

Inhibikase Therapeutics Inc. (IKT) download report

Healthcare | Biotechnology & Pharma Research

Inhibikase Therapeutics Inc. (IKT) Premium Coverage

52 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

Please wait...

Please wait...

Please wait...

Please wait...

Please wait...

About The Company

Business: Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain.

IPO Date: 23-Dec-2020

CEO, Pres & Director: Dr. Milton H. Werner Ph.D.

Chief Financial Officer: Mr. Joseph Frattaroli CPA

Listing: NASDAQ: IKT

Country: United States

Headquarters: Atlanta, GA

Website: https://www.inhibikase.com

Key Facts

Market cap: $22.64 Mln

Revenue (TTM): $1.74 Mln

Earnings (TTM): $-16.79 Mln

Cash: $36.61 Mln

Total Debt: $0.00 Mln

Insider's Holding: 21.32%

Liquidity: Low

52 Week range: $0.60 - 3.05

Shares outstanding: 25,227,100

6 Years Aggregate:

  • CFO: $-15.21 Mln
  • EBITDA: $-25.40 Mln
  • Net Profit: $-25.51 Mln

Stock Performance

Time Period Inhibikase Therapeutics (IKT) S&P BSE Sensex S&P Small-Cap 600
1 month7.13-2.87-2.72
3 months-43.06-8.59-12.17
1 Year-71.920.81-15.82
3 Years--10.397.14
5 Years--11.116.20
10 Years--12.0010.33
As on 24-Jun-2022
Year Inhibikase Therapeutics (IKT) S&P Small-Cap 600 S&P BSE Sensex